Fig. 8.

SELENOM regulates Parkin via the AMPKα1–MFN2 pathway. A, B The mRNA and protein expression levels of AMPKα1, MFN2 and Parkin were determined in HFD-treated livers with SELENOM^−/− (n = 6; *P < 0.05). C, D The mRNA and protein levels of AMPKα1, MFN2 and Parkin were determined in hepatocytes of Veh, SELENOM, PA, SELENOM + PA and SELENOM + PA + CC. Compound C (CC) was an inhibitor of AMPKα1 to block the activation of AMPKα1 (n = 3; *P < 0.05). E–G The immunofluorescent intensity of P-AMPKα1 and Parkin was verified via using the immunofluorescence assay in hepatocytes of Veh, SELENOM, PA, SELENOM + PA and SELENOM + PA + CC (n = 3; *P < 0.05). Fields from one representative experiment of three are shown (scale bar, 50 μm). Values represent means ± SEM. H Schematic representation of SELENOM promoting AMPKα1–MFN2 pathway in mitophagy of liver